Glycopyrrolate Injection is now available in Simplist ready-to-administer prefilled syringes in 2 dosage strengths.
Fresenius Kabi announced that the syringes will be available immediately in 0.2mg per 1mL and 0.4mg per 2mL dosage strengths. “For clinicians, particularly in the operating room, the need for clarity and convenience is real and we’re meeting that need with a pre-labeled, prefilled Glycopyrrolate syringe,” said John Ducker, president and CEO of Fresenius Kabi.
Fresenius Kabi also supplies Glycopyrrolate in vials of 0.2mg per 1mL, 0.4mg per 2mL, 1mg per 5mL and 4mg per 20mL.
Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection, may be used intraoperatively to counteract surgically or drug-induced, or vagal reflexes associated arrhythmias.
Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. It is also used in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.
For more information visit fresenius-kabi.com.